When we think about antimicrobial medications, antibiotics such as penicillin often come to mind. Penicillin and related antibiotics interfere with the synthesis of peptidoglycan cell walls, which effectively targets bacterial cells. These antibiotics are useful because humans (like all eukaryotes) do not have peptidoglycan cell walls.
Developing medications that are effective against eukaryotic cells but not harmful to human cells is more difficult. Despite huge morphological differences, the cells of humans, fungi, and protists are similar in terms of their ribosomes, cytoskeletons, and cell membranes. As a result, it is more challenging to develop medications that target protozoans and fungi in the same way that antibiotics target prokaryotes.
Fungicides have relatively limited modes of action. Because fungi have ergosterols (instead of cholesterol) in their cell membranes, the different enzymes involved in sterol production can be a target of some medications. The azole and morpholine fungicides interfere with the synthesis of membrane sterols. These are used widely in agriculture (fenpropimorph) and clinically (e.g., miconazole). Some antifungal medications target the chitin cell walls of fungi. Despite the success of these compounds in targeting fungi, antifungal medications for systemic infections still tend to have more toxic side effects than antibiotics for bacteria.
Parker, N., Schneegurt, M., Thi Tu, A.-H., Forster, B. M., & Lister, P. (n.d.). Microbiology. Houston, Texas: OpenStax. Access for free at: https://openstax.org/details/books/microbiology